Cencora (NYSE:COR) Price Target Raised to $405.00 at Wells Fargo & Company

Cencora (NYSE:COR) had its target price boosted by Wells Fargo & Company from $354.00 to $405.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 11.41% from the stock’s current price.

COR has been the subject of several other research reports. Robert W. Baird raised their price target on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. UBS Group lifted their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday. Wall Street Zen raised Cencora from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $360.55.

Cencora Trading Down 0.3%

Shares of NYSE:COR traded down $1.13 during midday trading on Tuesday, hitting $363.52. 40,794 shares of the stock were exchanged, compared to its average volume of 1,535,220. The business’s 50-day moving average price is $315.73 and its 200 day moving average price is $300.12. The stock has a market capitalization of $70.48 billion, a price-to-earnings ratio of 37.32, a P/E/G ratio of 1.56 and a beta of 0.63. Cencora has a 12 month low of $223.92 and a 12 month high of $366.03. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same quarter last year, the firm earned $3.34 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora will post 15.37 earnings per share for the current year.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 41,544 shares of company stock worth $12,230,941 over the last ninety days. Insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

Institutional investors have recently bought and sold shares of the stock. New York State Common Retirement Fund lifted its position in shares of Cencora by 3.7% during the first quarter. New York State Common Retirement Fund now owns 116,494 shares of the company’s stock valued at $32,396,000 after purchasing an additional 4,136 shares in the last quarter. CWM LLC increased its stake in Cencora by 0.9% in the 1st quarter. CWM LLC now owns 10,217 shares of the company’s stock valued at $2,841,000 after buying an additional 95 shares during the last quarter. Signaturefd LLC lifted its position in shares of Cencora by 3.9% during the 1st quarter. Signaturefd LLC now owns 3,755 shares of the company’s stock worth $1,044,000 after buying an additional 141 shares in the last quarter. Apollon Wealth Management LLC boosted its stake in shares of Cencora by 11.1% in the 1st quarter. Apollon Wealth Management LLC now owns 5,949 shares of the company’s stock worth $1,654,000 after buying an additional 596 shares during the last quarter. Finally, First Business Financial Services Inc. grew its holdings in shares of Cencora by 7.2% in the first quarter. First Business Financial Services Inc. now owns 14,559 shares of the company’s stock valued at $4,049,000 after acquiring an additional 974 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.